November 30, 2011 -- China biopharma Ascletis was nominated as the initial contender for InVivo Blog's contest that will choose the best Exit/Financing Deal of the Year from around the globe. Ascletis was chosen because its $100 million Series A funding was one of the highest ever for a biotech. Most Series A rounds are in the $5-$10 million range, and only 10% of this year’s initial fundings surpassed $40 million, making Ascletis's accomplishment a standout performance. More details....
